New hope for controlling severe bipolar mania
NCT ID NCT07288320
Summary
This study is testing whether a new investigational medicine called NBI-1117568 can help reduce severe manic symptoms in adults with bipolar I disorder who are currently hospitalized for a manic episode. The trial will compare the medicine to a placebo (an inactive substance) in about 150 participants over 21 days. The main goal is to see if the medicine improves manic symptoms more effectively than the placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR I DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurocrine Clinical Site
RECRUITINGGarden Grove, California, 92845, United States
-
Neurocrine Clinical Site
RECRUITINGHollywood, California, 33024, United States
-
Neurocrine Clinical Site
RECRUITINGSan Diego, California, 92123, United States
-
Neurocrine Clinical Site
RECRUITINGAtlanta, Georgia, 30331, United States
-
Neurocrine Clinical Site
RECRUITINGGaithersburg, Maryland, 20877, United States
-
Neurocrine Clinical Site
RECRUITINGMarlton, New Jersey, 08053, United States
Conditions
Explore the condition pages connected to this study.